iX Biopharma Ltd. 3Q26 and 9M26 Financial Analysis: Restructuring for Growth Amid Revenue Headwinds

iX Biopharma Ltd., a Singapore-listed pharmaceutical and wellness company, has released its unaudited condensed interim financial statements for the three and nine months ended 31 March 2026. The Group is actively commercialising its wellness portfolio, expanding into the US compounding pharmacy market, and leveraging proprietary sublingual drug delivery platforms. This article reviews the key financial metrics, strategic highlights, and outlook for investors.

Key Financial Metrics

Historical Performance and Trends

iX Biopharma’s revenue for both the quarter and nine-month period ended 31 March 2026 declined year-on-year, largely due to a 41-51% drop in third-party medicinal cannabis manufacturing volume. This was attributed to customer delays in securing raw material import clearances, challenging macroeconomic conditions in Australia, and a sector-wide contraction in medicinal cannabis. Conversely, the company’s nutraceuticals business delivered strong growth, with SL-NAD+ (a longevity supplement) accounting for 85% of new nutraceutical sales in 9M26. Gross margin improved significantly from 27% to 38% in the latest quarter, reflecting a more favourable sales mix and cost discipline.

Exceptional Earnings and Expenses

• The company recorded a net foreign exchange gain of \$1.04 million in 3Q26 and \$2.33 million in 9M26, mainly due to the appreciation of the Australian dollar against the Singapore dollar.
• Impairment on receivables and fair value loss on convertible bonds amounted to \$0.03 million each in 9M26, compared to higher impairments in the previous year.
• R&D expenses rose quarter-on-quarter due to new activities under a significant US Department of Defense (DoD) contract for Wafermine, but remained lower year-over-year due to cost controls in the first half.

Fundraising, Placements, and Share Dilution

• The company completed two private placements during the period, raising net proceeds of \$20.79 million. Warrant holders exercised \$0.45 million worth of warrants, and a further \$0.48 million was received for shares to be issued.
• Net asset value per share surged to 1.6 cents (from almost zero), with net assets increasing to \$17.01 million from \$0.37 million, largely due to equity inflows.
• No share buybacks or mandates were disclosed, but the company did not declare any dividends, choosing to conserve cash for development and commercialisation.

Cash Flow and Liquidity

• Net cash used in operating activities increased to \$4.87 million for 9M26 (vs. \$2.91 million in 9M25), mainly due to rebuilding of working capital. However, cash outflows before working capital changes fell by 8% year-over-year, reflecting improved cost management.
• Financing activities were a major driver of cash inflow, generating \$20.51 million, primarily from private placements and warrant exercises.
• Cash and cash equivalents rose sharply to \$16.49 million at period end, from \$0.87 million at 30 June 2025.

Directors’ Remuneration

Key management personnel received \$1.58 million in wages, salaries, and benefits for 9M26, slightly down from \$1.69 million in 9M25. Share-based payment expense was negligible in the latest period.

Macroeconomic and Industry Environment

The company notes continued macroeconomic headwinds, such as high inflation, interest rates, and supply chain disruptions in Australia, the US, and China. These factors are expected to constrain demand and input availability, especially for medicinal cannabis.

Major Contracts and Strategic Developments

• In February 2026, iX Biopharma was awarded a US\$40.95 million contract by the US Department of Defense to fund development and early commercial use of Wafermine, a patented sublingual ketamine wafer for acute pain. This contract will support both Emergency Use Authorization supply and pivotal Phase 3 development.
• The company is preparing to launch WaferiX, a direct-to-consumer nutraceutical platform in the US, and aims to expand into the US compounding pharmacy market via a joint venture with Orion Specialty Labs, LLC.
• Restructuring is underway to establish a US-based manufacturing and commercial entity, streamlining supply to the US and positioning for regulatory opportunities in peptide-based therapies.

Chairman’s Statement

“The Company is focused on actively commercialising its wellness portfolio and strategically expanding into compounding pharmacy channels in the United States (U.S.), backed by targeted and disciplined R&D that delivers clear near-term monetizable opportunities. This disciplined approach shifts us away from traditional, long-cycle drug development and aligns innovation with clear commercial pathways.” The tone is cautiously optimistic, emphasizing operational resilience, new commercial opportunities, and prudent cost management.

Dividends

No interim or final dividend has been declared for the current period, and no dividend was declared in the same period last year. The company is conserving cash for development and commercialisation.

Outlook

• While revenue was down year-over-year, the company’s successful fundraising and cost controls have strengthened the balance sheet and restored positive working capital.
• The DoD contract for Wafermine and the planned US expansion via compounding channels are expected to drive future growth.
• The company acknowledges ongoing macroeconomic challenges, particularly in Australia, which may continue to affect medicinal cannabis demand.

Recommendation

For Existing Shareholders: If you currently hold iX Biopharma shares, consider maintaining your position. The company’s improved liquidity, successful fundraising, and imminent US expansion offer a potential turnaround story, especially if the DoD contract and compounding pharmacy strategy deliver results. However, remain alert to ongoing revenue headwinds and macroeconomic risks.

For Prospective Investors: If you do not currently hold the stock, it may be prudent to watch for concrete execution of the US growth plan and signs of sustained revenue recovery before initiating a new position. The company has a unique technology platform and clear strategic direction, but risks remain around market demand and timing of commercialisation.

Disclaimer: This analysis is based solely on the company’s published interim results and does not take into account your personal investment objectives or financial situation. Please conduct your own due diligence or consult a professional advisor before making any investment decisions.

View IX BiopharmaW260718 Historical chart here